The Banook Group is one of the few international providers capable of supplying cardiac safety, central imaging and endpoint adjudication services to pharmaceutical groups, biotech companies, medical device manufacturers, CROs and nonprofit organizations.
Its mission is to help its clients develop the healthcare of tomorrow, using high quality, reliable and innovative solutions in all phases of clinical trials and ultimately to bring new solutions to market for the benefit of patients.
Its medical and regulatory expertise, quality-driven approach and team availability, make the Banook group a key player in clinical trials services.
Founded in 1999, the Banook Group operates on an international scale, maintaining offices at its headquarters in Nancy, (France), and in Montreal (Quebec, Canada)
nabios was founded in 1998 and has developed a strong expertise in cardiac safety assessments in clinical trials of drugs intended for human health. It supports pharmaceutical companies, Contract Research Organizations (CROs) and Clinical Pharmacology Units (CPUs), primarily in the conduct of Phase 1 clinical trials. nabios has a number of preferred provider partnerships, mostly based in Germany, including two of the top 20 big pharma companies and several Phase 1 units.
While becoming a part of the Banook Group, nabios will retain its current name built on its strong reputation. The Banook Group will strengthen its teams in Munich to enhance their presence in Central and Eastern Europe.